Musiliyu A Musa

Prof. Musiliyu A Musa


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2008 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Musiliyu A MusaMusiliyu A Musa
Musiliyu A Musa
JCJohn S. Cooperwood
John S. Cooperwood
MKM. Omar F. Khan
M. Omar F. Khan
The coumarin (benzopyran-2-one, or chromen-2-one) ring system, present in natural products (such as the anticoagulant warfarin) that display interesting pharmacological properties, has intrigued chemists and medicinal chemists for decades to explore the natural coumarins or synthetic analogs for their applicability as drugs. Many molecules based on the coumarin ring system have been synthesized utilizing innovative synthetic techniques. The diversity oriented synthetic routes have led to interesting derivatives including the furanocoumarins, pyranocoumarins, and coumarin sulfamates (COUMATES), which have been found to be useful in photochemotherapy, antitumor and anti-HIV therapy, and as stimulants for central nervous system, antibacterials, anti-inflammatory, anti-coagulants, and dyes. Of particular interest in breast cancer chemotherapy, some coumarins and their active metabolite 7-hydroxycoumarin analogs have shown sulfatase and aromatase inhibitory activities. Coumarin based selective estrogen receptor modulators (SERMs) and coumarinestrogen conjugates have also been described as potential antibreast cancer agents. Since breast cancer is the second leading cause of death in American women behind lung cancer, there is a strong impetus to identify potential new drug treatments for breast cancer. Therefore, the objective of this review is to focus on important coumarin analogs with antibreast cancer activities, highlight their mechanisms of action and structure-activity relationships on selected receptors in breast tissues, and the different methods that have been applied in the construction of these pharmacologically important coumarin analogs.

1 May 2007 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
Musiliyu A MusaMusiliyu A Musa
Musiliyu A Musa
MKM. Omar F. Khan
M. Omar F. Khan
JCJohn Cooperwood
John Cooperwood
Selective estrogen receptor modulators (SERMs), known previously as “antiestrogens”, are a new category of therapeutic agents used for the prevention and treatment of diseases such as osteoporosis and breast cancer. SERMs act as ERagonist in some tissues while acting as ER-antagonist in others based on conformational change of the receptors, particularly at the helix 12. Currently, there are two classes of clinically approved SERMs; triphenylethylene derivatives (e.g., tamoxifen) and benzothiophene derivatives (e.g., raloxifene). Tamoxifen, raloxifene and toremifene are the most widely used SERMs. Tamoxifen, an antagonist of the breast tissue, is the first clinically identified compound with noticeable SERM activity. Although tamoxifen has been very successful in breast cancer treatment, its agonistic effect on the uterus is said to be associated with increase risk of developing endometrial cancer. Ideally, it is presumed that SERMs should selectively act as an agonist in the bone and brain while simultaneously acting as an antagonist in the breast and uterus. Therefore, the therapeutic goal of SERMs is the prevention of estrogen deficiency diseases without promoting estrogen-associated tumor growth. Therefore, the objective of this review is to summarize various effects that have been applied in improving the tissue-selectivity of SERMs, highlighting the emerging understanding of their mechanism of actions in selected target tissues and the development of the SERMs. The significance in recent discovery of selective estrogen receptor alpha modulators, SERAMs will also be reviewed.

10 March 2003 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
PKPerry T. Kaye
Perry T. Kaye
Musiliyu A MusaMusiliyu A Musa
Musiliyu A Musa
XNXolani W. Nocanda
Xolani W. Nocanda
RRRoss S. Robinson
Ross S. Robinson
Evidence is presented which supports the intermediacy of dipolar Baylis–Hillman-type adducts in the synthesis of coumarin and chromene derivatives from the reaction of 2-hydroxybenzaldehydes with methyl acrylate in the presence of 1,4-diazabicyclo[2.2.2]octane (DABCO).

1 January 2004 in Synthetic Communications
Verified
Journal Article
Closed access
PKPerry T. Kaye
Perry T. Kaye
Musiliyu A MusaMusiliyu A Musa
Musiliyu A Musa
ANAloysius T. Nchinda
Aloysius T. Nchinda
XNXolani W. Nocanda
Xolani W. Nocanda
Hydroxyethylene dipeptide isosteres containing chromone, coumarin, chromene, and thiochromene moieties have been prepared as novel analogues of the human immunodeficiency virus (HIV)‐1 protease inhibitor, ritonavir.

7 March 2003 in Synthesis
Verified
Journal Article
Closed access
PDF file
PKPerry T. Kaye
Perry T. Kaye
Musiliyu A MusaMusiliyu A Musa
Musiliyu A Musa
XNXolani W. Nocanda
Xolani W. Nocanda
Reaction of substituted 2-hydroxybenzaldehydes with t-butyl acrylate in the presence of DABCO has been shown to afford isolable Baylis-Hillman adducts, acid-catalysed cyclisation of which affords the corresponding 3-(chloromethyl)coumarins directly and in high yield.

6 December 2002 in Synthesis
Verified
Journal Article
Closed access
PDF file
PKPerry T. Kaye
Perry T. Kaye
Musiliyu A MusaMusiliyu A Musa
Musiliyu A Musa
Halogen acid-catalysed deprotection and cyclisation of Baylis-Hillman products obtained using O-benzylated salicylaldehyde precursors has been shown to afford 3-(halomethyl)coumarins (3-halomethyl-2H-1-benzopyran-2-ones) chemoselectively and in good yield.